William Mack & Associates
HALO icon

William Mack & Associates’s Halozyme HALO Stock Holding History

William Mack & Associates’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.22K Buy
+11
New +$1.06K ﹤0.01% 679

Other funds holding HALO

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

William Mack & Associates's HALO Position: Q3 2026 in Review

William Mack & Associates opened a new position in Halozyme (HALO) in Q3 2026: 11 shares worth $1.22K. The stake represents ﹤0.01% of the portfolio and ranks #679 among its holdings.

636 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • William Mack & Associates held 11 shares of Halozyme worth $1.22K as of Q3 2026.
  • Halozyme was a new William Mack & Associates position in Q3 2026.
  • Halozyme made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #679 holding.
  • 636 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.